Introduction {#s1}
============

Melanoma is a malignant tumor originating from melanocytes and often occurs in the skin, uvea, oral cavity, intracranial, etc. ([@B59]; [@B61]; [@B69]). According to the global cancer statistics in 2018, there are more than 280,000 new cases of melanoma of skin worldwide, accounting for 1.6% of new cancer cases; and more than 60,000 cases of melanoma deaths worldwide, accounting for 0.6% of total cancer deaths ([@B6]). Although the morbidity and mortality of melanoma are not as high as other malignancies, the global burden of disease (GBD) of melanoma is increasing year by year. It is reported that the GBD of melanoma increased by 51% in 2016 compared with 2015, and the incidence of melanoma increased by 39% ([@B10]). In addition, the 5-year survival rate of advanced melanoma patients is only about 20% ([@B36]; [@B26]). For early melanoma, it can be cured by surgical treatment; moreover, immunotherapy, radiation therapy, chemotherapy, targeted therapy, and other treatments are used for the supplementary treatment of surgery or the treatment of patients with unresectable or metastatic melanoma ([@B65]).

As a form of biological therapy, immunotherapy is widely used to treat tumors. Some researchers believe that tumor cells develop and proliferate in the tumor microenvironment, while evading the identification and clearance of the immune system in a variety of ways ([@B64]). Due to the inhibition of the production and activity of immune effector cells in the body, many signals and factors were released to the tumor microenvironment to help tumor cells spread and metastasis. Immunotherapy can stimulate immune system, activate recognition surface antigens of tumor cells by immune cells, and induce immune cells to remove tumor cells, so as to achieve the purpose of cancer treatment ([@B41]). Up to now, many trials have been designed for immunotherapy of melanoma, including vaccines, immunomodulators, adoptive cell transfer therapy (ACT), immune checkpoint inhibitors (ICI), etc. ([@B31]). Vaccine induces immune response of immune system by active immunity, stimulates immune cells to recognize tumor specific antigens, and then destroys tumor cells. Common vaccines include dendritic cell (DC) vaccine, peptide vaccine, DNA vaccine, autologous tumor cell vaccine, etc. ([@B46]; [@B52]). Cytokines such as interleukin (IL)-2, IL-12, IL-15, and interferon-α (INF-α) can promote the immune recognition of melanoma and thus have function of regulating immunity ([@B42]). Adoptive cell immunotherapy separates lymphocytes from blood or tumor-infiltrating lymphocytes from tumors that have been surgically removed, and then transfuse them to patients after activation and proliferation *in vitro*, that to kill tumors or stimulate the anti-tumor immune effect of the body ([@B39]; [@B50]). In addition, immune checkpoint inhibitors (ICI), such as pembrolizumab and nivolumab, play a role in regulating the immune response of T lymphocytes in tumor microenvironment, and has made some progress in previous clinical trials ([@B48]).

Clinical trials of immunotherapy for melanoma continue to increase. In 1970s, the concept of "clinical trial registration" was proposed in the United States. Simes RJ ([@B58]) found that clinical trial with positive or promising outcomes was preferred to publish and the clinical trial registration helps to reduce this publication bias. Currently, the International Committee of Medical Journal Editors (ICMJE) requires all prospective clinical trials be registered before the first subject were included ([@B14]). In 2000, the *ClinicalTrials.gov* (<https://clinicaltrials.gov/>) was open to the public. As one of the most widely used clinical trial registration platform, its high weekly growth rates for new entries, high transparency and accessibility, and detailed information on past and present clinical trials ([@B35]), making *ClinicalTrials.gov* a representative of 16 clinical trial registry centers around the world ([@B72]). *ClinicalTrials.gov* has received more than 300,000 clinical trials registration so far, including a number of trials on immunotherapy for melanoma. Hence, more details could be obtained from trials than those reported in final peer-reviewed publications ([@B9]). Moreover, harnessing the immune system for therapeutic benefit in cancer becomes an aim of immunologists and oncologists in recent years. With the development of immunotherapy for melanoma, great progress has been made, but immune-related adverse events (irAE) have also observed. Therefore, we searched and analyzed all of these trials on immunotherapy for melanoma registered in *ClinicalTrials.gov* to assess the characteristics of them and the current status of immunotherapy.

Methods {#s2}
=======

Data Source {#s2_1}
-----------

We retrieved and downloaded all registered clinical trials for melanoma immunotherapy in the *ClinicalTrials.gov* website. We used its search function to search the term "melanoma" for "Condition or disease" and "Immunotherapy" for "Other terms" on August 1 (updated on August 25), 2019. Intervention (clinical trials), observation, and expanded studies were all included. Trials of open (not yet recruited, recruited) and closed (by invitation to register; active, unrecruited; suspended; terminated; completed; withdrawn; unknown) status were considered to include. There are no restrictions on the results of the study or the age of the patients enrolled. All finally included clinical trials must have a definitive record of established immunotherapy.

Statistical Analysis {#s2_2}
--------------------

The selected records were imported into the Microsoft Excel 2007 software and all of the following information was extracted: the NCT number, status, conditions, groups or arms, experimental and control medications, sponsor, collaborators, gender, age, study phases, enrollment, funder type, study types (allocation, intervention model, masking, primary purpose, and time perspective), start date, completion date, locations, data monitoring committee (DMC), US Food and Drug Administration (FDA)-regulated product, IPD sharing statement, study documents, and study result.

The general characteristics of clinical trials were shown in descriptive statistics. The categorical data was expressed by calculating the frequency and percentage. All analyses were performed using the Microsoft Excel 2007 software.

Results {#s3}
=======

General Characteristics of Included Clinical Trials {#s3_1}
---------------------------------------------------

A total of 395 records were identified on the *ClinicalTrials.gov*. After excluded repeated records, non-immunotherapy, and melanoma with other organ diseases trials, we finally include 242 trials. Among them, the vast majority of trials (n = 241, 99.6%) did not restrict gender of participants. Most trials (n = 224, 92.6%) were solely focused on adults, and a small number of trials (n = 18, 7.4%) were focused on both children and adults. The number of registered trials had increased significantly since 2008 ([**Figure 1**](#f1){ref-type="fig"}), and most trials (n = 154, 63.6%) began in 2011 and beyond. The majority of trials (n = 192, 79.3%) spanned more than 24 months, and more than one-third of the trials (n = 79, 32.6%) were over 60 months. Of the eligible trials, 233 (96.3%) were interventional, eight (3.3%) were observational, and one was expanded access trial. Most of them (n = 188, 77.7%) recruited less than 100 participants, only 4.6% recruited more than 400 participants. 74 trials (30.6%) were in the completed state, followed by the recruiting state (n = 65, 26.9%); 41 trials (16.9%) were terminated (lacking funds or statistical power, business reasons, expired commitment) and two were withdrawn (no patients were enrolled). [**Table 1**](#T1){ref-type="table"} presented the detailed information.

![Quantity trend of registered trials per year.](fphar-10-01539-g001){#f1}

###### 

General characteristic of included trials (n = 242).

  Name            Detail                   Number   Percent
  --------------- ------------------------ -------- ---------
  *Gender*                                          
                  All                      241      99.6%
                  Not provided             1        0.4%
  *Age*                                             
                  Adult                    224      92.6%
                  Child and adult          18       7.4%
  *Start Date*                                      
                  Prior to 2000            16       6.6%
                  2001--2010               70       28.9%
                  2011--2020               154      63.6%
                  Not provided             2        0.8%
  *During Date*                                     
                  0--12 months             7        2.9%
                  13--24 months            27       11.2%
                  25--36 months            36       14.9%
                  37--48 months            38       15.7%
                  49--60 months            39       16.1%
                  60-                      79       32.6%
                  Not provided             16       6.6%
  *Study Type*                                      
                  Interventional           233      96.3%
                  Observational            8        3.3%
                  Expanded access          1        0.4%
  *Enrollment*                                      
                  0--100                   188      77.7%
                  101--400                 35       14.5%
                  401\~                    11       4.6%
                  NP                       8        3.3%
  *Status*                                          
                  Active, not recruiting   39       16.1%
                  Completed                74       30.6%
                  No longer available      1        0.4%
                  Not yet recruiting       9        3.7%
                  Recruiting               65       26.9%
                  Suspended                3        1.2%
                  Terminated               41       16.9%
                  Unknown status           8        3.3%
                  Withdrawn                2        0.8%

Methodological Quality of Included Clinical Trials {#s3_2}
--------------------------------------------------

Among the 233 interventional trials, 95.5% were in Phase I to III. 71 (30.5%) were randomized, while 68 (29.2%) were non-randomized. The most common intervention model was single group assignment (n = 106, 45.5%), followed by parallel assignment (n = 101, 43.4%). Most of them (n = 207, 88.8%) were not masked, only eight (3.4%) were double masked, three (1.3%) were triple masked, and four (1.7%) were quadruple masked. Most (n = 227, 97.4%) commonly adopted primary aim were treatment. In addition, eight observational trials were cohort design, including five (62.5%) prospective design and three (37.5%) retrospective design. [**Table 2**](#T2){ref-type="table"} presented the detailed information.

###### 

Design data of included trials (n = 242).

  Study Type        Study Design               Number   Percent
  ----------------- -------------------------- -------- ---------
  Interventional                               233      96.3%
                    *Phases*                            
                    ·Phases 1--3               231      95.5%
                    ·Phase 4                   1        0.4%
                    ·Not applicable            1        0.4%
                    ·Not provided              9        3.7%
                    *Allocation*                        
                    ·Randomized                71       30.5%
                    ·Non-randomized            68       29.2%
                    ·Not provided              94       40.3%
                    *Intervention Model*                
                    ·Crossover assignment      4        1.7%
                    ·Factorial assignment      1        0.4%
                    ·Parallel assignment       101      43.4%
                    ·Sequential assignment     7        3.0%
                    ·Single group assignment   106      45.5%
                    ·Not provided              14       6.0%
                    *Masking*                           
                    ·None                      207      88.8%
                    ·Double                    8        3.4%
                    ·Triple                    3        1.3%
                    ·Quadruple                 4        1.7%
                    ·Not provided              11       4.7%
                    *Primary Purpose*                   
                    ·Diagnostic                1        0.4%
                    ·Prevention                1        0.4%
                    ·Treatment                 227      97.4%
                    ·Other                     3        1.3%
                    ·Not provided              1        0.4%
  Observational                                         
                    Cohort                     8        3.3%
                    ·Prospective               5        62.5%
                    ·Retrospective             3        37.5%
  Expanded Access                              1        0.4%

Detailed Characteristics of Included Clinical Trials {#s3_3}
----------------------------------------------------

In 242 trials, less than half (n = 107, 44.2%) had DMCs, 27.7% used immunization drugs were the US FDA-regulated products, eight trials (3.3%) had IPD sharing statement, seven trials (2.9%) had results submitted, 45 (18.6%) posted results on *ClinicalTrials.gov*, and 78.5% without any results posted. Nearly half of the trials (n = 114, 47.1%) had collaborations. 104 trials (43.0%) were sponsored by the industry, less than one-third (n = 66, 27.3%) were funded by the NIH, and 16.1% were funded only by NIH ([**Table 3**](#T3){ref-type="table"}). 148 trials (61.2%) were conducted in North America, then in the Europe (n = 47, 19.4%), and 9.9% were based on international cooperation ([**Figure 2**](#f2){ref-type="fig"}).

###### 

Detailed characteristics of included trials (n = 242).

  Name                           Detail                         Number   Percent
  ------------------------------ ------------------------------ -------- ---------
  *Data Monitoring Committee*                                            
                                 Yes                            107      44.2%
                                 No                             93       38.4%
                                 Not provided                   42       17.4%
  *U.S. FDA-regulated Product*                                           
                                 Yes                            67       27.7%
                                 No                             26       10.7%
                                 Not provided                   149      61.6%
  *IPD Sharing Statement*                                                
                                 Yes                            8        3.3%
                                 No                             41       16.9%
                                 Undecided                      19       7.9%
                                 Not provided                   174      71.9%
  *Results*                                                              
                                 Results submitted              7        2.9%
                                 Posted on ClinicalTrials.gov   45       18.6%
                                 No results posted              190      78.5%
  *Collaborators*                                                        
                                 Yes                            114      47.1%
                                 No                             128      52.9%
  *Funder type*                                                          
                                 NIH                            39       16.1%
                                 Industry                       49       20.3%
                                 Industry and (NIH+Other)       55       22.7%
                                 Other                          72       29.8%
                                 NIH and other                  27       11.2%

NIH, the National Institution of Health.

![Regional pie chart for included clinical trials.](fphar-10-01539-g002){#f2}

Description of Immunotherapies in Included Clinical Trials {#s3_4}
----------------------------------------------------------

All included trials involved four categories of immunotherapy: ACT, ICI, immunomodulators, and vaccine ([**Table 4**](#T4){ref-type="table"}). Among them, ICI was the most frequently (n = 155, 42.8%), followed by vaccine (n = 83, 22.9%). Among the ICI, the most studied were PD-1 (n = 83, 53.6%), followed by CTLA-4 (n = 64, 41.3%). The most studied single drug in PD-1 was nivolumab, followed by pembrolizumab. The most studied single drug in CTLA-4 was ipilimumab, and one study was tremelimumab. Among the vaccines, peptide vaccine was the most frequently studied vaccine, followed by DC vaccine, and then Autologous Tumor Cell vaccine. Among the immunomodulators, cytokines were the most widely studied, especially IL-2 (n = 50, 76.9%).

###### 

Descriptions of immunotherapies in clinical trials.

  Immunotherapies    Type of Drugs     Name of Drugs         Number   Percent
  ------------------ ----------------- --------------------- -------- ---------
  ICI                                                        155      42.8%
                     PD-1                                    83       53.6%
                                       Nivolumab^\*^         50       
                                       Pembrolizumab^\*^     30       
                                       Spartalizumab^\*^     2        
                                       Camrelizumab          1        
                     CTLA-4                                  64       41.3%
                                       Ipilimumab^\*^        63       
                                       Tremelimumab          1        
                     PD-L1             Atezolizumab^\*^      5        3.2%
                     LAG-3             Relatlimab            3        1.9%
  Immunomodulators                                           66       18.2%
                     Cytokine                                58       
                                       IL-2^\*^              50       
                                       IFN-α-2b              3        
                                       IFN-γ                 1        
                                       IL-12                 1        
                                       IL-15                 1        
                                       rIL-21                2        
                     TLRA              TLRA                  1        
                     Oncolytic viral   Oncolytic viral^\*^   6        
                     Not provided      Not provided          1        
  Vaccine            Vaccine                                 83       22.9%
                                       ATC                   12       
                                       BCG                   2        
                                       DNA                   5        
                                       DC^\*^                21       
                                       Dinitrophenyl         2        
                                       RNA                   4        
                                       Viral                 3        
                                       Peptide               34       
  ACT                                                        58       16.0%

\*U.S. FDA-regulated drug product; TLRA, toll-like receptor agonist; ATC, autologous tumor cell.

Discussion {#s4}
==========

This study comprehensively analyzed drug trials registered on *ClinicalTrials.gov*, all of which explored immunotherapy and common adverse reactions to melanoma. Through analysis, we found most of the trials were interventional trials, and one third trials had been completed. Most interventional trials were phase 1--3, small sample size, and single group assignment, not blinded, for therapeutic purposes. At the same time, nearly half of the trials included the data monitoring committee, and one fifth submitted and published results. ICI and vaccine were the most widely studied immunotherapies, of which ipilimumab, nivolumab, and IL-2 were the most single drug widely studied.

Almost all subjects in these trials were gender-neutral, and more than 92% of the trials included only adults. Even though women diagnosed with cutaneous melanoma have a survival advantage due to the effects of sex hormones, there is no difference in overall survival rates between men and women ([@B18]). Although melanoma often occurs in adults, it is also the most common skin cancer in children ([@B17]). According to these registrations, only a few trials have been included children; obviously, there is still a great shortage of research on melanoma in children. Hence, we recommend researchers expand scope of the population in future clinical trials to get more clinical data for children with melanoma. Since 2008, more than 10 trials have been conducted each year, and 63% of trials have been carried out after 2010. The registration of clinical trials helps to increase the sharing of information of clinical trials, increase the openness of the research process, and reduce publication bias ([@B4]). In 2004, the ICMJE issued a statement requesting that prospective clinical trials need to be registered prior to inclusion in patients ([@B14]). From this study, we found the number of clinical trial registrations for melanoma immunotherapy has increased significantly compared to before after 2004, this may be related to this publication policy.

More than 96.3% were interventional studies, and among them only 30.5% clearly indicated random allocation was used, 43.4% used parallel assignment models, and only 6.4% used double-masking, triple-masking, or quadruple-masking. Randomization is a very powerful method that can largely prevent confusion and reduce selection bias in treatment comparisons ([@B56]). The implementation of masking can bring many benefits to participant, care provider, investigator, and outcomes assessor ([@B54]). However, due to the different toxicity profiles of the comparators, the trials were difficult to perform blindly, so most of them were open label design. More than 64% of the research continued for three years or more, and 79 trials were conducted for more than five years. Because melanoma is invasive, patients with stage IV melanoma have an average survival of about eight months and a low five-year survival rate ([@B24]). Most clinical trials were still exploring the long-term survival of immunotherapy for melanoma ([@B20]; [@B53]). According to result of enrollment, the sample size of most studies was still small, and 77% included fewer than 100 patients. The sample size affects population mean, variance, statistical power, and effect size ([@B16]), which is directly related to the credibility of the results ([@B51]). Therefore, this suggested that the minimum sample size should be estimated in advance in the design stage of clinical trials to meet the accuracy and reliability of statistics and ensure the reliability of results.

Most of the selected trials were conducted in North America, and 9.8% were conducted on more than two continents. The *ClinicalTrials.gov* is a database of privately and publicly funded clinical studies conducted around the world, which currently contains registration information for nearly 300,000 studies in more than 200 countries ([@B63]). 47.1% of trials had collaborators, 50% were conducted by NIH participate in sponsorship. Rare adverse events are unlikely to be found in small sample clinical studies, because the effect size may be too small to be evaluated. One way to increase the sample size is to conduct multi-center collaborative research to increase the external validity of the study ([@B71]). At the same time, the support of funds from sources such as the NIH provides a strong guarantee for the smooth development of multi-center research ([@B1]). 44.2% of the trials had DMCs, and DMC is critical to maintaining the scientific integrity of the trial, the accuracy and authenticity of the trial data, and the safety of the study participants ([@B21]). 21.5% of the trials submitted or posted their results, although the reporting rate had improved, but still need to adhere to the principle to provide accurate, complete, and timely information for all studies ([@B72]). 27.7% of the trials reported FDA-regulated product, and federal law requires sponsors to submit summary results for applicable clinical trials, including those following the first phase of the FDA new drug approvals to *ClinicalTrials.gov* for public releasing ([@B55]).

The included trials were classified according to the type of immunotherapy. The results showed that most studies explored ICI and vaccines, among the ICI, the most studied were PD-1, followed by CTLA-4. The most studied single drug in PD-1 was nivolumab, followed by pembrolizumab. The most studied single drug in CTLA-4 was ipilimumab. Immunological checkpoint inhibitors (ICI) have greatly changed the treatment of advanced skin melanoma and gradually replaced traditional chemotherapy, showing great potential for the treatment of melanoma. Common ICIs include cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies ([@B43]), programmed cell death protein 1 (PD-1) antibodies ([@B62]), PD-L1 antibodies ([@B60]), and lymphocyte-activation gene-3 (LAG-3) antibodies ([@B43]). CTLA-4 and PD-1 downregulate T cell response in lymphoid tissues and tumor microenvironments. And their monoclonal antibodies can interfere with this pathway and promote the activation of anti-cancer T cells ([@B34]). PD-L1 binds to PD-1 on T cells, which down-regulates T cell activity, and PD-L1 antibodies achieve anti-tumor effects by interfering with this pathway ([@B73]). LAG-3 is another important immunological checkpoint, and co-expression of PD-1 is associated with T cells exhaustion ([@B25]; [@B47]). Common monoclonal antibodies corresponding to these four types of ICI are ipilimumab (NCT00324155), nivolumab (NCT01585194), atezolizumab (NCT03175432), and relatlimab (NCT03743766).

Vaccine is a hot spot drug and made some progress in the immunotherapy of melanoma. Among the vaccines, peptide vaccine was the most frequently studied vaccine, followed by DC vaccine, and then autologous tumor cell vaccine. Most cancer vaccines are designed to activate tumor-specific CD8^+^ cytotoxic T cells, so the most common peptide vaccination strategy is based on MHC class I-restricted peptide epitopes on TAA ([@B8]). DCs are the most effective antigen presenting cell in the immune system and have the unique ability to induce the differentiation of naive T lymphocytes into effector T cells, which have specific cytotoxic activity against a variety of antigens, including antigens expressed by tumor cells ([@B3]). The principle of DC vaccine preparation is to collect lymphocytes from peripheral blood, induce them into DC *in vitro*, and present tumor antigens to DCs, thereby providing a large number of these cells for active immunotherapy ([@B12]). Tumor antigen presentation to DC can be accomplished in a variety of ways ([@B45]; [@B66]). A new method was developed to present autologous tumor antigens to the cytoplasm of DCs. This method is more effective than conventional foreign aid loading. In the mouse melanoma model, the new method produces DC vaccines that show more excellent effect ([@B27]). Geskin *et al.* conducted the efficacy of three MODC vaccines for the treatment of metastatic melanoma, differing only in the antigen loading method of autologous tumors: co-culture, fusion, or lysate pulse, and found vaccines to be safe with few side effects ([@B23]). Other common vaccines such as recombinant vaccinia virus, plasmid DNA vaccine, autologous tumor cell vaccine, and dinitrophenyl (DNP)-modified melanoma vaccine are still in the stage of clinical trials. Although monotherapy with these vaccines is unlikely to produce substantial complete remission or cure rates in metastatic melanoma, the use of these vaccines to promote anti-tumor immunity may be an important method of future combination therapy ([@B68]).

Immunomodulators are an important part of melanoma immunotherapy ([@B42]). Common immunomodulators are cytokines such as IL-2, IL-12, IL-15, and IFN. These cytokines can help lymphocytes to recognize melanoma and achieve the purpose of treating tumors ([@B37]; [@B40]). IFN-α and IL-2 have been used in the immunotherapy of melanoma for decades ([@B7]). High-dose IL-2 is one of the first immunotherapeutic drugs to demonstrate initial clinical efficacy in advanced cancer patients ([@B5]). The US-FDA approved it in 1996 for the treatment of metastatic malignant melanoma (MM). However, due to the high toxicity of HD IL-2, it is rarely used in clinical trials to treat MM patients ([@B70]). Davar *et al.* ([@B13]) retrospectively analyzed data from 237 patients receiving high-dose (HD) IL-2 from 1992 to 2015. The results showed that the overall response (OR) was 18.1% and complete response (CR) was 8.0%. The median overall survival (OS) was 64.9 months. In addition, this study found that pre-treatment level of lactate dehydrogenase (LDL) and sites of metastatic disease may be useful markers for patients who benefit from HD IL-2 therapy. The anti-tumor effect of IFN-α is expected to be induced by CD8+ T cell-mediated autologous tumor cell lysis. High-dose IFN is currently the standard adjuvant therapy, despite the high incidence of adverse events ([@B19]). The significant clinical efficacy of oncolytic virus ([@B2]) and toll-like receptor agonist ([@B38]) had opened up a new path for melanoma immunotherapy, and follow-up clinical research is underway. It is expected that it will have better clinical research results and be used in clinical practice as soon as possible.

ACT is another hot spot in immunotherapy for melanoma. Common adoptive cells include tumor infiltrating lymphocytes (TIL) ([@B33]), chimeric antigen receptor modified T cells (CAR-T) ([@B67]), and T cell receptor (TCR) gene modified T cells ([@B32]). TIL is a lymphocyte isolated from tumor tissue. After induction by interleukin-2 *in vitro*, TIL can be amplified in large quantities ([@B29]). A clinical trial of TIL treatment for melanoma was followed up to 17 years. The results showed that the major adverse events experienced during treatment were transient and reversible, with no grade 3/4 toxicity or drug-related death observed. The recurrence-free survival of the TIL group was 14 months and nearly 4 months longer than the control group ([@B30]). CAR-T cells are a promising approach in adoptive cell therapy for melanoma. The technique requires screening a monoclonal antibody that specifically recognizes certain tumor antigens, and then coupling the binding region of the antibody to certain peptide chains on the T cell surface membrane molecule to construct a chimeric antigen receptor; then, it is introduced into the patient\'s T cells for expression, and its ability to specifically recognize the antigen is activated to exert an anti-tumor effect ([@B22]; [@B44]). One study has shown a way to stabilize the production of CAR-T cells ([@B67]). In addition, genetic modification of T cells by altering the specificity of TCR is another strategy of ACT. The antigen specificity of T cells can be manipulated by genetic modification and targeted to antigens expressed by tumors. The production of tumor-specific TCR requires identification of target sequences in advance, then tumor-specific T cells are isolated from patients with tumor remission, and the reactive TCR sequences are transferred to T cells from another patient ([@B15]). The tumor killing activity can be enhanced by altering the sequence of TCR to T cells *in vitro* to increase the strength of interaction of TCR with antigen ([@B49]; [@B57]).

Immunotherapy has revolutionized the treatment of cancer. At the same time, given this growing success, treatment response rates, duration of treatment, why patients respond or not, and if combined with different immunotherapy will overcome this lack of response, delay acquired resistance and increase ([@B11]). There are major limitations and unresolved issues in terms of opportunities for success. Given the complexity of immune activation and the considerable variability of tumor biology in patients and tumor types, it is necessary to understand the body\'s immune pathways, the molecular and immune basis of the disease, and develop interventions and combinatorial strategies that are more suitable for the treatment of cancer patients. Explore patient choices and biomarkers ([@B28]). Although immunotherapy has shown promising success, further and ongoing research is needed to determine safety, efficacy, optimal combination, dosage, and timing. Our study also has some limitations. This study only retrieves trials in the *ClinicalTrials.gov*, although approximately two-thirds of total global registrations, we might miss some trials registered in other 15 registration centers ([@B72]) that were not fully evaluated. All information is obtained from the *ClinicalTrials.gov*, and some information of registration trials that has not been submitted to the website, therefore, some studies cannot be fully evaluated.

In conclusion, up to now, most clinical trials related to melanoma immunotherapy registered in the *ClinicalTrials.gov* were interventional trials; and although the number of registered studies increases gradually every year, the number of registered trials was still small. At the same time, it is encouraged to register on the clinical trial registration platform. In addition, we noticed that the results of some clinical trials were not uploaded to registration platform after the end of the trial. It is suggested that the researchers of clinical trials update the latest results of the trial regularly, which will help disseminate information in this field and help doctors get the research frontier as soon as possible. Although some adverse reactions may occur in the course of immunotherapy for melanoma, as an effective treatment for melanoma and even other malignant tumors, we should increase our energy and financial investment in the exploration of immunotherapy.
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